. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Radiother Oncol. 2015 Aug 4;117(1):77–82. doi: 10.1016/j.radonc.2015.07.024

Table 2.

The 4 SNP candidates advanced from Step-1 to Step-2 to form SNP-signatures, and the 2 SNP-signatures advanced from Step-2 to Step-3.

SNPs or SNP-signatures	Genotypes	Patient number (% of patient)		P value
SNPs or SNP-signatures	Genotypes	Distribution	Two-year OS	P value
ERCC2: rs238406	GG	30 (33%)	6 (20%)	0.005
ERCC2: rs238406	not GG (GT+TT+0)	62 (67%)	31 (50%)	0.005
ERCC1: rs11615	CC	13 (14%)	3 (23%)	0.07
ERCC1: rs11615	not CC (CT+TT+0)	79 (86%)	34 (43%)	0.07
ERCC1: rs3212948	GG	12 (13%)	3 (25%)	0.20
ERCC1: rs3212948	not GG (CG+CC+0)	80 (87%)	34 (43%)	0.20
XRCC4 rs9293329	AG	11 (12%)	3 (27%)	0.28
XRCC4 rs9293329	not AG (AA+GG+0)	81 (88%)	34 (42%)	0.28
Signature1:rs238406/rs11615	GG in rs238406 or CC in rs11615	38 (41%)	9 (24%)	0.006
Signature1:rs238406/rs11615	The others	54 (59%)	28 (52%)	0.006
Signature2:rs238406/rs9293329	GG in rs238406 or AG in rs9293329	36 (39%)	9 (25%)	0.01
Signature2:rs238406/rs9293329	The others	56 (61%)	28 (50%)	0.01